Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy (Q45796080)

16 December 2017

title

Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy (English)

1 reference

16 December 2017

1 reference

1 reference

1 reference

Oliver J Stoetzer

1

1 reference

16 December 2017

Debora M I Fersching

2

1 reference

16 December 2017

Christoph Salat

3

1 reference

16 December 2017

Oliver Steinkohl

4

1 reference

16 December 2017

Christian J Gabka

5

1 reference

16 December 2017

Ulrich Hamann

6

1 reference

16 December 2017

Michael Braun

7

1 reference

16 December 2017

Axel-Mario Feller

8

1 reference

16 December 2017

Volker Heinemann

9

1 reference

16 December 2017

Barbara Siegele

10

1 reference

16 December 2017

Dorothea Nagel

11

1 reference

16 December 2017

Stefan Holdenrieder

12

1 reference

16 December 2017

publication date

15 September 2012

1 reference

16 December 2017

published in

Tumor Biology

1 reference

16 December 2017

volume

34

1 reference

16 December 2017

issue

1

1 reference

16 December 2017

page(s)

81-90

1 reference

16 December 2017

https://scigraph.springernature.com/pub.10.1007/s13277-012-0513-1

exact match

0 references

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Prognostic and predictive factors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Apoptotic markers in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

HMGB1 and RAGE in inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Immunological aspects of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Molecular characteristics of immunogenic cancer cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

High mobility group box 1 protein interacts with multiple Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Immunogenic cell death modalities and their impact on cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Serum cathepsin K and cystatin C concentration in patients with advanced non-small-cell lung cancer during chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

High-mobility group box 1 and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Plasma nucleosome levels might predict response to therapy in patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Nucleosomes in pancreatic cancer patients during radiochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Tumor markers in breast cancer- European Group on Tumor Markers recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Receptor for Advanced Glycation End Products (RAGE)—Soluble Form (sRAGE) and Gene Polymorphisms in Patients with Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0513-1

Clinical use of circulating nucleosomes

21 January 2018

1 reference

12 December 2020

Nucleosomes in colorectal cancer patients during radiochemotherapy

1 reference

12 December 2020

Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer

1 reference

12 December 2020

Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma

1 reference

12 December 2020

Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

12 December 2020

Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin

1 reference

12 December 2020

Methodological and preanalytical evaluation of an HMGB1 immunoassay

1 reference

12 December 2020

Methodological and preanalytical evaluation of a RAGE immunoassay

1 reference

12 December 2020

Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients

1 reference

12 December 2020

Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy

1 reference

12 December 2020

Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer

1 reference

12 December 2020

Early and specific prediction of the therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragments

1 reference

12 December 2020

Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access BR Monitor assay on the UniCel Dxl 800 Immunoassay System

1 reference

12 December 2020

Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update

1 reference

12 December 2020

Factors masking HMGB1 in human serum and plasma

1 reference

12 December 2020

10.1007/S13277-012-0513-1

Identifiers

DOI

1 reference

16 December 2017

Dimensions Publication ID

0 references

1 reference

16 December 2017